

R&D portfolio

Product List 2020

Product	Pharmaceutical Form	Strengths	Therapeutic Category	Dossier Status
Rosuvastatin + Ezetimibe	Tablets	5mg+10mg 10mg+10mg 20mg+10mg 40mg+10mg	Cholesterol & Triglyceride regulator	Ready
Prednisolone	Oral solution	1mg/ml 10mg/ml	Corticosteroids for systemic use	Ready
Cholecalciferol	Hard gel capsules	10.000 IU 25.000 IU	Treatment or prevention of vitamin D deficiency	Ready
Sitagliptin Hydrochloride	F.C. Tablets	25mg 50mg 100mg	Oral antidiabetic	Q4 2020
Sitagliptin Hydrochloride + Metformin	F.C. Tablets	50mg+500mg 50mg+850mg 50mg+1000mg	Oral antidiabetic	Q3 2020
Micafungin	Powder for solution for infusion	50mg/10ml 100mg/10ml	Antifungal	Q1 2021
Rivaroxaban	F. C. Tablets	2,5mg 10mg 15mg 20mg	Oral anticoagulant	Q1 2021

Product	Pharmaceutical Form	Strengths	Therapeutic Category	Dossier Status
Ticagrelor	F.C. Tablets	60mg 90mg	Platelet aggregation inhibitor	Q1 2021
Apixaban	F.C. Tablets	2.5mg 5mg	Oral anticoagulant	Q4 2021
Dapagliflozin	F.C. Tablets	5mg 10mg	Oral antidiabetic	Early development
Dapagliflozin + Metformin	F.C. Tablets	5mg+850mg 5mg+1000mg 10mg+850mg 10mg+1000mg	Oral antidiabetic	Early development
Vortioxetine	F.C. Tablets	5mg 10mg 20mg	Antidepressant	Early development

Products which are subject to patent are currently not offered or made available in countries where patents are in force. No orders or deliveries, prior to patent expiry are possible.

Contact Pharmazac

Athens

Business Development & Licensing

Naousis 31

Athens, 10447

Greece

Tel.: +30 210 341 8889

Fax.: + 30 210 866 1262

E-mail.: bd@pharmazac.com

Exports

Naousis 31

Athens, 10447

Greece

Tel.: +30 210 341 8889

Fax.: + 30 210 866 1262

E-mail.: exports@pharmazac.com

London

Corporate Development
152-160 City Street
London EC1V 2NX
United Kingdom
Tel.: + 44 7583444774
E-mail.: cd@pharmazac.com